Introduction Preoperative weight loss has been suggested as a predictor of postoperative weight loss outcomes after Metabolic Bariatric Surgery (MBS). While previous studies focused on outcomes up to 3 years, longer-term results remain limited. This study evaluates the association between preoperative weight loss and total weight loss (%TWL) up to five years postoperatively. Methods This single-center retrospective study included 765 patients who underwent primary MBS between June 2017 and august 2019. Patients were stratified into quartiles based on preoperative weight loss. Follow-up data on %TWL were analyzed at 3 and 6 months and 1 through 5 years postoperatively. Results The median age was 45 (35-52) and the majority were female (76.6%). Most patients underwent ring augmented Roux-en-Y Gastric Bypass (91.1%). Follow-up was 99.6% at 1 year and 65.9% at 5 years. Quartiles were defined as Q1: <4.4%, Q2:4.4-6.2%, Q3: 6.2-8.2% and Q4: > 8.2% preoperative weight loss. After 5 years %TWL was 32.4 (Q1), 32 (Q2), 32 (Q3) and 31.6 (Q4). Conclusion Greater preoperative weight loss was associated with significant higher %TWL up to two years (quartiles) and four years (low vs high) after MBS, but no significant differences were found after five years of follow up. The impact of preoperative weight loss on long-term outcomes was consistent across subgroups. Female sex, RYGB procedure and younger age were general predictors for greater %TWL.
BACKGROUND:Currently, no comprehensive overview exists of response and survival outcomes for first-line immune checkpoint inhibition, BRAF/BRAF + MEK inhibition (BRAF(/MEK)i), and talimogene laherparepvec (T-VEC) in melanoma patients with unresectable in-transit metastases (ITM). This study aims to provide a real-world overview of these outcomes. METHODS:Using data from the nationwide Dutch Melanoma Treatment Registry, all patients receiving systemic treatment from 2012 to July 2025 for unresectable ITM, with or without lymph node metastases (LNM) (stage III-IVM1a), were analysed for overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS). A multivariable Cox model adjusted for age, sex, ECOG PS, LDH, and LNM. RESULTS:In total, 530 patients were identified: 213 received first-line anti-PD1, 182 T-VEC, 67 BRAF(/MEK)i, 37 ipilimumab (IPI), and 31 ipilimumab + nivolumab (IPI+NIVO). Patients receiving T-VEC had more favorable baseline characteristics, including less often stage IV disease, less often LNM, and lower LDH. ORR were comparable between treatments: anti-PD1 53.1%, T-VEC 52.2%, BRAF(/MEK)i 62.7%. Median PFS was significantly shorter for T-VEC (5.6months; 95%CI 4.2-8.1) than for anti-PD1 (8.1months; 95%CI 5.9-13.8) and BRAF(/MEK)i (9.2months; 95%CI 6.9-14.3). Median OS favored T-VEC (not reached (NR); 95%CI 61.5-NR) over anti-PD1 (37.2months; 95%CI 32.3-64.7) and BRAF(/MEK)i (24.7months; 95%CI 18.0-62.1), but this difference between T-VEC and anti-PD1 disappeared after adjusting for confounders and no differences were observed in MSS. In the ITM-only subgroup, T-VEC-treated patients demonstrated longer observed OS than anti-PD1 and BRAF(/MEK)i, while in patients with ITM and LNM, anti-PD1 showed longer PFS but similar OS compared with T-VEC. CONCLUSIONS:For ITM unresectable melanoma, first-line anti-PD1, T-VEC, and BRAF(/MEK)i can induce clinically meaningful and durable responses. The optimal treatment choice depends on patient and disease characteristics and preferences.
Laparoscopic Adjustable Gastric Band (AGB) has shown suboptimal long-term results with a non-success rate of 20–56
Osteoporotic spine fractures deeply affect patients’ lives, yet little is known about patients’ lived experiences. This qualitative study found that patients face delayed diagnosis, inconsistent care, and emotional distress, while professionals call for clearer communication and coordination. Results highlight the urgent need for more consistent, patient-centered osteoporosis care. Osteoporotic vertebral compression fractures (OVCFs) are common and often debilitating, yet patient perspectives remain underexplored. This study aimed to investigate the lived experiences of patients with OVCF and the perspectives of healthcare professionals involved in their care. A qualitative research design was used, involving 25 semi-structured interviews with postmenopausal women with a symptomatic OVCF (n = 15) and healthcare providers (n = 10) across six Dutch hospitals. Thematic analysis was performed using ATLAS.ti. After initial familiarization, data were organized into categories and subcategories. Coding was iterative, and 25